Improving Gene Therapy Safety with High-Sensitivity Impurity Profiling that Identifies Hidden Contaminants Across the Process

• Pinpointing where HCPs, residual DNA, and process-related contaminants accumulate across upstream, downstream, and final formulation to give teams a proactive risk profile
• Evaluating when LC-MS, DIA-MS, ddPCR and immunoassays complement each other to ensure no single assay misses critical contaminants
• Linking impurity patterns to potency drift, vector quality, and safety signals

Speakers:

Ricardo Gomes

Senior Research Associate

IBET - Instituto de Biologia Experimental e Tecnologica